Inclusion Criteria:

- diagnosis of MM as per IMWG criteria

- age greater than 17 years

- have received at least 2 but no more than 4 prior lines of therapy

- have failed to respond to the most recently administered anti-MM therapy or have
demonstrably progressive disease as defined by accepted standard criteria

- have a life expectancy of at least 3 months

- ECOG performance status < 3

- at registration haematological values within the following limits:

1. absolute neutrophil count (ANC) > 1.0 x 109/L

2. platelet count > 50 x 109/L unsupported

- At registration biochemical values within the following limits

1. Bilirubin < 1.5 x upper limit of normal (ULN) and transaminases < 2 x ULN unless
considered secondary to hepatic myelomatous infiltration

2. Serum creatinine < 0.19mMol/L

- Written informed consent

- Must agree to use adequate contraceptive measures if indicated. Specifically, women
of childbearing potential (WOCBP) may participate provided they meet the following
conditions:

1. Agree to use at least 2 effective contraceptive methods throughout the study and
for 30 days following the study

2. Have a negative serum pregnancy test within 24 hours of commencing on study
medication

3. Male participants with female partners that are WOCBP must agree to use 2
effective contraceptive methods throughout the study and for 30 days following
the study

Exclusion Criteria:

- Patients with monoclonal gammopathy of undetermined significance (MGUS) or
indolent/smouldering MM

- Known or suspected hypersensitivity to AZA or mannitol

- Patients whose general condition makes them unsuitable for intensive treatment e.g.
significant cardiac or pulmonary disease

- Active infections or other illnesses that precludes chemotherapy administration or
patient compliance

- Active viral infection with known human immunodeficiency virus (HIV) or viral
hepatitis type B or C

- Pregnant or lactating women